会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明公开
    • 항 HIV 제
    • 抗艾滋病毒药物
    • KR1020020068299A
    • 2002-08-27
    • KR1020020009001
    • 2002-02-20
    • 니홍 케미칼 리써치 가부시키가이샤
    • 와다마나부와다나오꼬
    • A61K39/395
    • A61K38/49A61K2039/505C07K16/2896
    • PURPOSE: Provided are novel type of anti-HIV agents particularly for inhibiting reproduction of HIV in an individual infected with the virus. The anti-HIV agents act by a mechanism of action different from those already being clinically used or under development. CONSTITUTION: The anti-HIV agent comprises as an active component a ligand molecule binding to CD87. An anti-HIV pharmaceutical composition comprises as an active component ATF, or a fragment thereof or an analogue thereto having a specific binding affinity to CD87. A method for screening for an anti-HIV agent comprises separately bringing compounds to be tested into contact with CD87 and selecting from the compounds a compound that specifically binds to CD87. A method for preparing an anti-HIV pharmaceutical preparation comprises the steps of: separately bringing compounds to be tested into contact with CD87 and selecting from the compounds a compound that specifically binds to CD87; confirming that the selected compound has an anti-HIV activity; and providing the compound confirmed to have an anti-HIV activity, as an anti-HIV agent, in the form of a pharmaceutical preparation to be administered to a human.
    • 目的:提供特别用于在感染病毒的个体中抑制HIV繁殖的新型抗HIV药物。 抗艾滋病毒药物的作用机制与已经在临床使用或正在开发中的行动不同。 构成:抗HIV剂包含与CD87结合的配体分子作为活性成分。 抗HIV药物组合物包含与CD87具有特异性结合亲和力的活性成分ATF或其片段或类似物。 用于筛选抗HIV药物的方法包括将待测化合物单独地与CD87接触并从化合物中选择特异性结合CD87的化合物。 制备抗HIV药物制剂的方法包括以下步骤:将待测化合物分别与CD87接触并从化合物中选择特异性结合CD87的化合物; 确认所选择的化合物具有抗HIV活性; 并提供被确认为具有抗HIV活性的化合物作为抗HIV剂,其形式为待给予人的药物制剂。
    • 19. 发明公开
    • 나트륨 이온 구동형 클로라이드/비-카르보네이트 익스체인저
    • 四氯化碳/二氯乙烷交换器
    • KR1020020013454A
    • 2002-02-20
    • KR1020010048008
    • 2001-08-09
    • 니홍 케미칼 리써치 가부시키가이샤세이노 스스무
    • 세이노스스무야노히데끼왕창쳉
    • C07K14/62
    • C07K14/705
    • PURPOSE: Provided are human and mouse Na-driven Cl/HCO3 exchanger (sodium ion-driven chloride /bicarbonate exchanger) proteins, which are a class of proteins involved in intracellular pH regulation, and a method for selecting agonists/antagonists of the sodium ion-driven chloride/bicarbonate exchanger proteins. CONSTITUTION: DNAs comprise nucleotide sequences of SEQ ID NO:1 or NO:3 encoding Na(+)-driven Cl(-)/HCO3- exchanger. Proteins comprise amino acid sequences of SEQ ID NO:2 or NO:4, and their homologous proteins comprise an amino acid sequence having deletion, substitution, addition or insertion amino acids, which proteins, when expressed in a cell, function as Na(+)-driven Cl(-)/HCO3- exchanger, and cells in which the proteins exogenously expressed.
    • 目的:提供人和小鼠Na驱动的Cl / HCO3交换剂(钠离子驱动的氯化物/碳酸氢盐交换剂)蛋白,其是参与细胞内pH调节的一类蛋白质,以及选择钠离子的激动剂/拮抗剂的方法 氯仿/碳酸氢盐交换蛋白。 构成:DNA包含编码Na(+) - 驱动的Cl( - )/ HCO 3 - 交换剂的SEQ ID NO:1或NO:3的核苷酸序列。 蛋白质包含SEQ ID NO:2或NO:4的氨基酸序列,并且它们的同源蛋白质包含具有缺失,取代,添加或插入氨基酸的氨基酸序列,当在细胞中表达时,该蛋白质以Na(+ ) - Cl( - )/ HCO 3 - 交换剂,以及蛋白质外源表达的细胞。